		U.S	S. PATENT DOCUMENTS	- 100
Exr Initials	U.S. Patent Docume Number	ent Kind Code (if known)	Name of Inventor or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
96,	4,861,670		Mazuel et al.	08-29-1989
	4,847,091		Illum	07-11-1989
	4,946,870		Pertain III et al.	08-07-1990
	5,204,108		Illum	04-20-1993
	5,327,883		Williams et al.	07-12-1994
	5,422,097		Gwaltney et al.	06-06-1995
	5,482,706		Igari, et al.	01-09-1996
	5,554,388		Illum	09-10-1996
	5,589,453		Greve	12-31-1996
	5,690,954		Illum et al.	11-25-1997
	5,707,644		Illum	01-13-1998
PG	5,730,983		Wegner et al.	03-24-1998

	<u>.</u>	Foreign Patent Docum	ent		Date of	T ₁	
Exr Initials	Country Number Code		Kind Code (if known)	Name of Inventor or Applicant of Cited Document	Publication of Cited Document MM-DD-YYYY		
PO	WO	90/05522	A1	Prisell, et al.	05-31-1990		
]	WO	91/06282	A1	Danbiosyst UK Ltd.	05-16-1991		
	WO	93/06842	A1	Boehringer Ingelheim Pharm.	04-15-1993		
	WO	94/00485	A1	Miles, Inc.	01-06-1994		
	WO	94/27576	A1	Danbiosyst UK Ltd.	12-08-1994		
	EP	0 223 303	A1	N.V. Philips	05-27-1987		
	EP	0 314 863	B1	Baylor College of Medicine	05-10-1989		
	EP	0 362 531	A1	Molecular Therapeutics, Inc.	04-11-1990		
	GB	1 518 121		Pharmacia Aktiebolag	07-19-1978	\Box	

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Ex Initia	als	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book, also include publisher and city and/or county where published.	T ₁
П	Page	AL-NAKIB, et al., "Suppression of Colds in Human Volunteers Challenged with Rhinovirus by a New Synthetic Drug (R61837)," <i>Antimicrobial Agents and Chemotherapy</i> 33(4):522-526 (1989).	
П	-	DEASY, et al., "Rheological evaluation of deacetylated gellan gum (Gelrite) for pharmaceutical use," International Journal of Pharmaceutics, 73:117-123 (1991).	
	^	FLORENCE, et al., Physicochemical Principles of Pharmacy, (2 nd ed.), Ch. 8, pp 281-333, (MacMillan Press, 1988).	
P	آس.	HAYDEN, et al., "Prevention of Natural Colds by Contact Prophylaxis with Intranasal Alpha ₂ -Interferon", New England Journal of Medicine 314(2):71-75 (1986).	

Examiner Signature PHICLIP GAMBEL	1/1/03	Date Considered
-----------------------------------	--------	--------------------

Form PT	O/SB/08B	·		JAN 3 0 2002 KS	Complete if Known	一页	٦
l				Application/Number	09/848,600	三王	
INFOR	MATION	DISCLO	OSUR	Filing Date	May 3, 2001	Ω	Ţ
STATE	MENT B	Y APPL	ICANT \	Filing Date	Peter Watts	2	7 :
				Gr up Art Unit	1644		$\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ $
(use a	as many sh	eets as ne	ecessary)	Examiner Name	Phillip Gambel		7
Sheet	2	of	2	Attorney Docket Number	10774-23U1 (WESZ/P14288US)	<u> </u>	7

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	8
Exr Initials	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book, also include publisher and city and/or county where published.	29
136.	ILLUM, "The nasal delivery of peptides and proteins", <i>Trends in Biotechnology</i> 9(8):284-289 (1991).	
	ILLUM, "Nasal delivery of peptides, factors affecting nasal absorption", in <u>Topics in</u> <u>Pharmaceutical Science</u> , Ch. 5, pp. 71-82 (1991).	
	KUBLIK, et al., "Rheological Properties of Polymer Solutions as Carriers for Nasal Drug Delivery Systems," <i>European Journal of Pharmaceutics and Biopharmaceutics</i> 39(5):192-196 (1993).	
	MARLIN, et al., "A soluble form of intercellular adhesion molecule-1 inhibits rhinovirus infection" <i>Nature</i> 344:70-72 (1990).	
~	NAGAI, et al., "Application of Chitin and Chitosan to Pharmaceutical Preparations," <i>Proc. Jt. US-Jpn. Seminar Adv. Chitin, Chitosan, Relat. Enzymes</i> 21-39 (Academic Press, Orlando) (1984).	
7.	SANZGIRI, et al., "Gellan-based systems for ophthalmic sustained delivery of methylprednisolone," <i>Journal of Controlled Release</i> 26:195-201 (1993).	
-	SAWAYANAGI, et al., "Dissolution Properties and Bioavailability of Phenytoin from Ground Mistures with Chitin or Chitosan," <i>Chem. Pharm. Bull.</i> 31(6):2062-2068 (1983).	
-	VON ITZSTEIN, et al., "Rational design of potent sialidase-based inhibitors of influenza virus replication," <i>Nature</i> 363:418-423 (1993).	
	AHERN, et al. "Chemical and Physical Pathways of Protein Degradation," Pharmaceutical Biotechnology, Vol. 2, Part A, Stability of Protein Pharmaceuticals, pp. 124-125 (Plenum Press, New York) (1992).	
-	BANKER, et al. Modern Pharmacutics (3 rd edition), pp. 852-853 (Marcel Dekker, Inc., New York) (1996).	
,	LEE, Peptide and Protein Drug Delivery, pp. 36-37, 148-151 (Marcel Dekker, Inc., New York) (1991).	
,	MCNÁLLY, Protein Formulation and Delivery, pp.32-35, 40-41,130-133 (Marcel Dekker, Inc.) (2000).	
16-	FLORENCE, et al., <u>Physicochemical Principles of Pharmacy</u> , (3 rd edition), Ch. 11, pp. 504-505, (Macmillan Press, 1998).	
		

Examiner Signature	PHILLIPGAMBEL 1/2/03	Date Considered
0.9.10.0		33.13.13.13